Pages that link to "Q45100550"
Jump to navigation
Jump to search
The following pages link to Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease (Q45100550):
Displaying 11 items.
- Dopamine receptors and Parkinson's disease (Q35545020) (← links)
- In vivo microdialysis in Parkinson's research. (Q37735813) (← links)
- New non-oral drug delivery systems for Parkinson's disease treatment (Q37840165) (← links)
- Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease (Q38155589) (← links)
- Dopamine receptor agonists for Parkinson's disease. (Q38169202) (← links)
- Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease (Q38682342) (← links)
- The neuroprotective action of candesartan is related to interference with the early stages of 6-hydroxydopamine-induced dopaminergic cell death (Q44377363) (← links)
- Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance (Q47868277) (← links)
- Efficacy of oral lipid-based formulations of apomorphine and its diester in a Parkinson's disease rat model (Q48268483) (← links)
- The habenula couples the dopaminergic and the serotonergic systems: application to depression in Parkinson's disease (Q48447380) (← links)
- Degree of dopaminergic degeneration measured by 99mTc-TRODAT-1 SPECT/CT imaging (Q64864808) (← links)